Study of Neoantigen mRNA Vaccines in Patients With Resectable Pancreatic Cancer
Status:
RECRUITING
Trial end date:
2026-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and efficacy of treating pancreatic cancer with surgery to remove cancerour tissue, followed by camrelizumab and a personalized cancer mRNA vaccines.
Phase:
EARLY_PHASE1
Details
Lead Sponsor:
Jinling Hospital, China
Collaborator:
Jiangsu Synthgene Biotechnology Co.Ltd.
Treatments:
camrelizumab Drug Therapy Immune Checkpoint Inhibitors Surgical Procedures, Operative